Wells Fargo
KYTX icon

Wells Fargo’s Kyverna Therapeutics KYTX Stock Holding History

Wells Fargo’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$987K Buy
114,399
+39,450
+53% +$329K ﹤0.01% 3746
2025
Q4 		$705K Buy
74,949
+56,669
+310% +$421K ﹤0.01% 4221
2025
Q3 		$110K Buy
18,280
+14,948
+449% +$59.8K ﹤0.01% 5271
2025
Q2 		$10.2K Sell
3,332
-13,346
-80% -$33K ﹤0.01% 5947
2025
Q1 		$32.2K Sell
16,678
-162,334
-91% -$480K ﹤0.01% 5541
2024
Q4 		$670K Buy
179,012
+25,225
+16% +$121K ﹤0.01% 3987
2024
Q3 		$752K Buy
153,787
+41,078
+36% +$317K ﹤0.01% 3730
2024
Q2 		$845K Buy
112,709
+100,803
+847% +$1.54M ﹤0.01% 3602
2024
Q1 		$296K Buy
+11,906
New +$332K ﹤0.01% 4229

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Wells Fargo's KYTX Position: Q1 2026 in Review

Wells Fargo increased its Kyverna Therapeutics (KYTX) stake by 53% in Q1 2026, buying an estimated $329K and bringing the position to 114,399 shares worth $987K. The position accounts for ﹤0.01% of the portfolio, ranked #3746.

Wells Fargo first reported a position in KYTX in Q1 2024 and has held it in 9 quarters since. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • Wells Fargo held 114,399 shares of Kyverna Therapeutics worth $987K as of Q1 2026.
  • Wells Fargo bought 39,450 Kyverna Therapeutics shares in Q1 2026, an estimated $329K.
  • Kyverna Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #3746 holding.
  • Wells Fargo first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.